Company: ARTL
Filing Date: 2025-07-11
Form Type: S-1
Source: 0001640334-25-001190
Chunk: 4

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-07-11
Form: S-1
Chunk 4
---
     |      |  8 |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS |     |      | 12 |
| USE OF PROCEEDS                                   |     |      | 13 |
| DIVIDEND POLICY                                   |     |      | 14 |
| SELLING SECURITYHOLDERS                           |     |      | 15 |
| PLAN OF DISTRIBUTION                              |     |      | 18 |
| PRINCIPAL STOCKHOLDERS                            |     |      | 20 |
| DESCRIPTION OF CAPITAL STOCK                      |     |      | 22 |
| LEGAL MATTERS                                     |     |      | 25 |
| EXPERTS                                           |     |      | 25 |
| WHERE YOU CAN FIND MORE INFORMATION               |     |      | 25 |
| INCORPORATION OF CERTAIN INFORMATION BY REFERENCE |     |      | 26 |

| i |

<div align='center'>ABOUT THIS PROSPECTUS</div>

As used in this prospectus, unless the context otherwise requires or indicates, references to “the Company,” “we,” “our,” “ourselves,” “us” and “Artelo” refer to Artelo Biosciences, Inc.

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”), under which the Selling Securityholders may, from time to time, sell the securities described in this prospectus in one or more offerings or otherwise described under “Plan of Distribution.”

We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. Such prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.”

Neither we, nor the Selling Securityholders, have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we